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OBJECTIVE—Pancreatic-derived factor (PANDER, FAM3B) is
a pancreatic islet-speciﬁc cytokine-like protein that is secreted
from -cells upon glucose stimulation. The biological function of
PANDER is unknown, and to address this we generated and
characterized a PANDER knockout mouse.
RESEARCH DESIGN AND METHODS—To generate the
PANDER knockout mouse, the PANDER gene was disrupted and
its expression was inhibited by homologous recombination via
replacement of the ﬁrst two exons, secretion signal peptide and
transcriptional start site, with the neomycin gene. PANDER
/
mice were then phenotyped by a number of in vitro and in vivo
tests to evaluate potential effects on glucose regulation, insulin
sensitivity, and -cell morphology and function.
RESULTS—Glucose tolerance tests demonstrated signiﬁcantly
higher blood glucose levels in PANDER
/ versus wild-type male
mice. To identify the mechanism of the glucose intolerance,
insulin sensitivity and pancreatic -cell function were examined.
Hyperinsulinemic-euglycemic clamps and insulin tolerance test-
ing showed similar insulin sensitivity for both the PANDER
/
and wild-type mice. The in vivo insulin response following intraperi-
toneal glucose injection surprisingly produced signiﬁcantly higher
insulin levels in the PANDER
/ mice, whereas insulin release was
blunted with arginine administration. Islet perifusion and calcium
imaging studies showed abnormal responses of the PANDER
/
islets to glucose stimulation. In contrast, neither islet architecture
nor insulin content was impacted by the loss of PANDER. Interest-
ingly, the elevated insulin levels identiﬁed in vivo were attributed to
decreased hepatic insulin clearance in the PANDER
/ islets.
Taken together, these results demonstrated decreased pancreatic
-cell function in the PANDER
/ mouse.
CONCLUSIONS—These results support a potential role of
PANDER in the pancreatic -cell for regulation or facilitation of
insulin secretion. Diabetes 59:2209–2218, 2010
P
ancreatic-derived factor (PANDER, FAM3B) is a
235–amino acid protein secreted predominantly
from pancreatic - and -cells that appears to
colocalize with both insulin and glucagon (1,2).
The initial discovery of PANDER was the result of a
computational algorithm, ostensible recognition of folds
(ORF), in an attempt to identify novel cytokines based on
the prediction of secondary structure. From ORF, it was
hypothesized that the secondary structure of PANDER
contained a four-helix bundle with a typical up-up-down-
down topology, also found in numerous cytokines.
Initial in vitro experiments evaluating the impact of
PANDER on pancreatic islets demonstrated the induction
of apoptosis in primary islets (mouse, human, and rat) or
islet-derived cell lines either by exogenous recombinant
protein application or intracellular adenoviral delivery via
a caspase-3–dependent mediated mechanism (2–4). Fur-
thermore, microarray analysis of PANDER-treated islets
demonstrated the activation of various cell death path-
ways via both caspase-3 and cyclin-dependent kinase
inhibitor 1A (p21) (5). However, despite these in vitro
results demonstrating a potential role for PANDER in islet
apoptosis, our ﬁrst animal model exploring the function of
PANDER did not recapitulate these ﬁndings.
Transgenic mice that have pancreatic-duodenal ho-
meobox-1 (PDX-1)–driven targeted overexpression of
PANDER, speciﬁcally in pancreatic -cells, display normal
-cell mass and function, but exhibit a glucose-intolerant
phenotype after a high-fat diet (6). The mechanism of this
observed glucose intolerance is still being elucidated. How-
ever, the liver is a potential target for PANDER and may be
central to the observed glucose intolerance (7). Iodinated
recombinant PANDER has been shown to bind to liver
membranes. Pretreatment of liver-derived HepG2 cells with
PANDER resulted in signiﬁcant inhibition of insulin-stimu-
lated activation of the insulin receptor, insulin receptor
substrate-1, phosphatidylinositol-3-OH-kinase (PI-3 kinase),
and Akt, indicating the potential involvement of PANDER in
regulation of hepatic insulin-signaling pathways.
Further evidence of PANDER’s potential role in regulat-
ing glycemia has been generated by the inﬂuence of
glucose on PANDER expression. Glucose has been dem-
onstrated to 1) increase secretion of cleaved PANDER and
production of full-length PANDER in both insulinoma cells
and primary islets (8), 2) upregulate PANDER mRNA (9),
and 3) induce promoter activity (10). In addition, the
critical pancreatic -cell–speciﬁc transcriptional factor of
PDX-1 binds to the PANDER promoter (11). Glucose has
been demonstrated to induce PANDER gene expression
via multiple signaling pathways that include Ca
2 protein
kinase A (PKA), extracellular signal–regulated kinase 1/2
(ERK-1/2), and cAMP-responsive element-binding protein
(CREB), as well as Ca
2 protein kinase C (PKC) and CREB
mechanisms (9). Furthermore, glucose-regulated PANDER
gene expression in MIN6 cells is dependent on both PI-3
kinase– and reactive oxygen species–related pathways.
Much of the data surrounding PANDER certainly sug-
gest a potential role in glucose homeostasis, but the lack of
a knockout animal model has hindered the elucidation of
the biological function of PANDER. To address this, we
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PANDER knockout mouse. Deletion of PANDER resulted
in glucose intolerance with impaired insulin secretion,
revealing an unpredicted role for PANDER in pancreatic
-cell function.
RESEARCH DESIGN AND METHODS
Construction of PANDER targeting vector and knockout mice. A mouse
129/Sv-genomic bacterial artiﬁcial chromosome clone containing 14 kb of the
PANDER sequence with the ﬂanking DNA of our potential targeted region was
used as a template to create both the long and short arms of the targeting
vector. An approximate 4.3-kb long-arm genomic fragment containing the
PANDER promoter was ampliﬁed by forward primer 5-GCGGTACCGCCCT
GGCTGTTCTGGAACTAA-3 and reverse primer 5-GAGGATCCGACCCAGT
GTGGTGCCAA-3 and was cloned in opposite orientation of the neomycin
gene using the KpnI and BamH1 sites within cloning site A of the OSDupDel
(courtesy of Youhai Chen, University of Pennsylvania) plasmid (incorporated
restriction sites are italicized) (Fig. 1A). The approximate 2.9-kb short-arm
genomic fragment containing intron 2 of the PANDER gene was ampliﬁed with
forward primer 5-GGCACGTGCTGTCATTCAAGCATTGGGA-3 and reverse
primer 5-GCGCTAGCCTTCAACAAATAGGGTTCTA-3, and was cloned into
the cloning site B using the PmlI and NheI sites, respectively. The thymidine
kinase gene was inserted at the 3 end of the short arm of the targeting vector
for negative selection. This targeting vector was created to remove the ﬁrst 54
amino acids of PANDER, encompassing the transcriptional and translational
start site, secretion signal peptide, and helix A. From a total of 288 clones
generated by the University of Pennsylvania Gene Targeting Core, 2 that were
correctly recombined were identiﬁed by PCR . Correct insertion of the 5 arm
and replacement of a portion of the PANDER gene with neomycin was
conﬁrmed by PCR ampliﬁcation using the forward primer located in the
PANDER promoter region of 5-CTTGTGATGGTGGATGCCCAGTT-3 and the
reverse primer located in the neomycin gene of 5-CTTCCTCGTGCTTTACG
GTATC-3. Conﬁrmation of the 3 arm was performed with the forward primer
located in the neomycin gene of 5-CCGAATAGCCTCTCCACCCAA-3 and
reverse primer located in intron two of the PANDER gene of 5-GCCACTGC
CACTAAAGAAAGA-3. Both primer sets were used under the following
cycling conditions: 1 cycle at 94°C for 2 min, 35 cycles at 94°C for 30 s, 60°C
for 30 s, and 68°C for 4 min and 30 s, followed by 1 cycle of 68°C for 5 min
using Accuprime TaqDNA polymerase (Stratagene). Chimeric mice were
produced by microinjection of the correctly targeted cell clone into E3.5
C57BL/6 blastocysts and transferred to pseuodopregnant foster mothers. High
percentage male chimeras (70% or greater) were then chosen for subsequent
mating with C57BL/6 females, and germline transmission was conﬁrmed by
PCR as described above. Chimeras were subsequently generated from the
targeted embryonic stem (ES) cells and bred to C57BL/6 mice with germ line
transmission. PANDER
/ mice were subsequently bred to homogeneity, and
genomic conﬁrmation was performed by PCR using primers to encompass the
entire targeted region. Primers used for this PCR conﬁrmation are described
above as the forward primer located in the 5 PANDER promoter region and
the reverse primer located in intron 2. PCR conditions were the same as
described above with the exception of the extension cycle, which was
increased from 68°C for 4 min and 30 s to 12 min. The wild-type PANDER gene
resulted in a 12.1-kb product, and the recombinant PANDER knockout allele
resulted in an 8.3-kb product. All mouse procedures adhered to protocols
approved by the University of Pennsylvania and Children’s Hospital of
Philadelphia Institutional Animal Care and Use Committee.
Quantitative analysis of gene expression via RT-PCR. Various tissues
were collected from PANDER
/,
/, and
/ mice and immediately snap
frozen in RNAlater (Qiagen). RNA was then isolated using the RNeasy Kit
(Qiagen) following the manufacturer’s instructions. Purity and quantity of the
isolated RNA was determined by the A260/A280. RT-PCR of the PANDER gene
was performed as previously described (2). Primers for detection of various
genes involved in glucose-stimulated insulin secretion were purchased com-
mercially (Applied Biosystems). Relative levels of mRNA expression were
normalized to -actin or 18S rRNA and calculated using the 2
-CT method.
Immunoblotting. Pancreatic islets were isolated from mice using the stan-
dard collagenase method as previously described (2). Cell lysates were
prepared, analyzed, and electrotransferred to polyvinylidine ﬂuoride (PVDF)
membrane as previously described (2). Detection was performed using a
rabbit polyclonal PANDER antibody that was produced via Genomic Antibody
Technology (Strategic Biosolutions). Immunoblots were incubated with pri-
mary antibody at a dilution of 1:1,000 in 1 Tris-buffered saline with Tween
(TBST) (10 mmol/l Tris base, 100 mmol/l NaCl, 0.1% Tween-20, pH 7.5) and 2%
blocking solution (GE Healthcare) at 4°C overnight. The membrane was
washed ﬁve times with 10 ml 1 TBST, incubated in 1:20,000 peroxidase-
conjugated donkey anti-rabbit antibody at room temperature for 1 h before
washing as above and then developed with enhanced chemiluminescence. For
conﬁrmation of equivalent loaded protein, following the detection of the
PANDER immunoblot, PVDF membrane was stripped with Restore Western
Blot Stripping Buffer (Pierce Biotechnology) and reprobed using 1:500 -actin
antibody (sc-8432; Santa Cruz Biotechnology). Detection was performed using
the enhanced chemiluminescence Western blotting detection reagents (GE
Healthcare). Measurement of glucokinase (sc-7908) and Kir6.2 (sc-20809)
expression in pancreatic islets was performed as described above.
Glucose/insulin tolerance and arginine stimulation tests. For glucose
tolerance tests (GTTs), mice were fasted overnight (16 h) and subsequently
injected intraperitoneally with 2 grams of glucose (Fisher Scientiﬁc) per kilogram
of body weight. Glucose levels were measured at 0, 15, 30, 60, 90, and 120 min
with a Freestyle glucometer via tail vein blood sampling (5 	l). Measurement of
plasma insulin concentration during the GTT was performed by obtaining blood
collected from the tail vein in a Microvette CB 300 (Sarstedt), followed by
centrifugation for serum separation and collection. Sera samples were then
frozen at 80°C prior to insulin content analysis. Plasma insulin levels were
determined by using the Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem).
For insulin tolerance tests, mice were fasted for 4 h and then injected intraperi-
toneally with 0.75 units of insulin (NovoLog) per kilogram of body weight.
Glucose levels were measured as described above. For arginine stimulation tests,
mice were fasted overnight and then injected intraperitoneally with 2 grams of
arginine (Sigma) per kilogram of body weight. Blood glucose and serum insulin
levels were obtained as described above.
Hyperinsulinemic-euglycemic clamp and hepatic glucose production
calculation. Clamp studies were performed and calculations were deter-
mined by the University of Pennsylvania Mouse Phenotyping Core as previ-
ously described (12).
Islet perifusion studies. Islet perifusions were performed as previously
described (3). In brief, freshly isolated and hand-picked murine islets (100)
were collected under a stereomicroscope, washed twice with Krebs-Ringer
bicarbonate buffer (KRB), and loaded into a 13-mm chamber containing a
nylon membrane ﬁlter held at 37°C in a water bath. Islets were ﬁrst perifused
with KRB containing 0 mmol/l glucose for 1 h followed by a run perifusion
consisting of increasing glucose conditions. Insulin content of efﬂuent frac-
tions and islet lysate were determined by radioimmunoassay.
Immunoﬂuorescence. Immunoﬂuorescence was performed on pancreatic
sections as described previously, using confocal microscopy (Leica Microsys-
tems) (2). The following antibodies were used: guinea pig anti-insulin (1:200
dilution; Linco), mouse antiglucagon (1:200 dilution; R&D Systems), anti-
guinea pig alexa-ﬂuor488 (1:5,000; Invitrogen), and anti-mouse alexa594
(1:5,000; Invitrogen).
Calcium imaging of isolated pancreatic islets. Murine pancreatic islets
were isolated as described above and cultured for 3 days in complete RPMI.
Islets were pooled from three mice per each genotype and then loaded with 15
	mol/l fura-2 acetoxymethylester (fura-2AM) (Molecular Probes). Calcium
imaging of the isolated islets was performed as described before (13). In brief,
fura-2AM–loaded islets were then transferred to a perifusion chamber and
placed on a homeothermic platform of an inverted Zeiss microscope for
calcium evaluation with a 40 oil-immersion objective. Islets were then
perifused with KRB at 37°C at a ﬂow rate of 2 ml/min while increasing
concentrations of glucose in KRB were applied with a terminal application of
30 mmol/l KCl. Intracellular calcium concentration was determined by the
ratio of the excitation of fura-2AM at 334 nm to that at 380 nm. Emission was
measured at 520 nm with an Attoﬂuor Ratio Vision Software (BD Biosciences).
ATP and ADP assays. ATP and ADP content was measured from 100 isolated
murine islets pooled from two mice per each genotype and then stimulated
during static incubation with glucose as previously described (14).
Hepatic insulin clearance. For estimating insulin clearance, the ratio of
C-peptide (ng/ml) over insulin (ng/ml) area under the curve (AUC) was calculated
from the mean serum levels obtained during a GTT (described above) from
multiple time points (0, 30, and 120 min post-intraperitoneal glucose injection).
Insulin concentrations were calculated as described earlier, and C-peptide levels
were determined using the Mouse C-Peptide II ELISA (ALPCO).
Measurement of glucagon-like peptide-1. Mice were fasted overnight (16
h) and then exposed to a 4-h refeed in which chow was added back to
respective cages, and the mice were allowed to feed ad libitum. After the
refeeding period, mice were killed and blood was collected in a Microvette CB
300 (Sarstedt), followed by centrifugation for serum separation and collection.
Sera samples were then frozen at 80°C prior to glucagon-like peptide-1
(GLP-1) analysis. Total GLP-1 levels were determined from 50 	l of sera using
the GLP-1 (7–36 and 9–36) ELISA kit (ALPCO).
Statistical analysis. Data are presented as mean 
 SEM. Statistical signiﬁ-
cance of differences between groups was analyzed by paired Student t test
using programs resident to Graphpad Prism version 5.01. A P value less than
0.05 was considered statistically signiﬁcant.
IMPAIRED -CELL FUNCTION IN PANDER
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Generation and conﬁrmation of PANDER knockout
mice. The PANDER gene was disrupted in ES cells by
homologous recombination using a targeting vector that
would replace the ﬁrst two exons (54 amino acids), secretion
signal peptide, and transcriptional start site with the neomy-
cin gene inserted in the opposite orientation (Fig. 1A). Of the
288 ES clones, 2 were identiﬁed as correctly targeted (Fig.
1B) and used to generate chimeric male mice that passed
the disrupted PANDER gene to the offspring (Fig. 1C).
PANDER
/ mice were then bred to homogeneity to create
PANDER
/ knockouts (Fig. 1D).To conﬁrm the complete
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FIG. 1. Generation and conﬁrmation of the PANDER knockout (KO) mouse. A: Schematic representation of genomic arrangement for mouse PANDER
(top), targeting vector (middle), and the disrupted locus (bottom) produced by homologous recombination. The targeting vector was created by cloning
a 4.3-kb long arm and 2.9-kb short arm of ﬂanking PANDER genomic sequence surrounding the neomycin (NEO) gene in opposite orientation, intended
to disrupt the transcriptional start site (TSS), secretion signal peptide (SP), and exons 1 and 2. Primers 5-F/5-R and 3-F/3-R were used for
conﬁrmation of correct gene targeting, resulting in a 4.3-kb and 3.5-kb product, respectively. Primers 5-F/3-R were used for routine PCR genotyping
producing a 12.1-kb product for wild-type (WT), 12.1-kb/8.3-kb products for heterozygote (HET), and single 8.3 kb for KO. B: PCR analysis of genomic
DNA extracted from transfected ES cells. Primer locations are shown in Fig. 1A. Lane 1: molecular marker; lanes 2 and 3: 4.3-kb arm ampliﬁed from
two independent correctly targeted ES cell clones; lanes 4 and 5: 3.5-kb arm from correctly targeted ES cell clones; lanes 6 and 7: lack of 5 and 3 arm
ampliﬁcation from negative ES clones; and lane 8: 4.3-kb product from artiﬁcial template consisting of a plasmid containing the 5 arm sequence with
ﬂanking nontargeted genomic regions. C: PCR conﬁrmation of germline transmission. Genomic DNA was extracted from tail biopsies of mouse offspring
with subsequent PCR using the 5-F/5-R primers. Lane 1: molecular marker; lanes 2, 3, 5, and 8: mouse offspring negative for germline transmission;
and lanes 4, 6, 7: mouse offspring with targeted PANDER deletion. D: Genotyping of mouse offspring. Representative PCR results are shown among WT,
HET, and KO mice. E: RT-PCR analysis of RNA isolated from PANDER-positive tissues from WT, HET, and KO mice. F: Western evaluation of protein
isolated from pancreatic islets for PANDER (top) and -actin (bottom) expression from WT, HET, and KO mice.
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PANDER- restricted tissues of pancreatic islets and intes-
tine, both RT-PCR and Western blot analysis were per-
formed. PANDER mRNA expression was evaluated in the
various PANDER-negative tissues of liver, spleen, kidney,
and brain and in the PANDER-positive tissues of isolated
pancreatic islets and small intestine. PANDER mRNA was
not detected above background in both islets and small
intestine from PANDER
/ mice, with marked reduc-
tion found in PANDER
/ mice (Fig. 1E). As expected,
PANDER message was not detected in PANDER-negative
tissues (data not shown). Western blot analysis of protein
isolated from pancreatic islets of PANDER
/ mice demon-
strated the absence of full-length PANDER protein, whereas
a marked reduction was observed in heterozygotes (Fig. 1F).
Metabolic evaluation of PANDER
/ mice. PANDER
/
mice were intercrossed to generate a total of 233 offspring
born with the expected Mendelian distribution with no
observed increase in embryonic lethality (data not
shown). There were no signiﬁcant differences in size,
appearance, or 24- or 48-h fasting levels of glucose, insulin,
and glucagon among PANDER
/,
/, and
/ mice
(data not shown). We initially evaluated the impact of
PANDER deletion on glucose tolerance. GTTs demon-
strated higher blood glucose levels in PANDER
/ versus
wild-type 4- to 6-month-old male mice (Fig. 2A). Glucose
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FIG. 2. Metabolic evaluation of PANDER
/ mice. A: Intraperitoneal GTT performed by injecting mice with glucose at 2 g/kg and measuring serum
glucose concentration at the indicated time points (n  14). B: AUC calculated from glycemic levels measured during the course of the GTT. C:
Intraperitoneal insulin tolerance test performed by injecting mice with insulin at 0.75 units/kg and measuring glucose concentration at indicated time
points (n  8). D: Mean steady-state glucose infusion rate (GIR) during hyperinsulinemic-euglycemic clamp (n  8). E: Measured insulin levels during
GTT (n  14). F: Intraperitoneal arginine tolerance test. Arginine was injected at 2 g/kg (n  8–9). For all experiments above, male mice 4–6 months
old were evaluated. Values are means  SE. *P < 0.05. **P < 0.01 by Student t test. n.s., not signiﬁcant; KO, knockout; WT, wild-type.
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male mice (data not shown). Glucose intolerance was not
observed in littermate and genotype-matched females
(data not shown). After glucose injection, the elevation in
blood glucose levels was signiﬁcantly higher in PAN-
DER
/ mice compared with wild-type mice for a majority
of the evaluated time-points, with a signiﬁcant difference
observed (P  0.001) when determining total AUC for all
glucose readings during the course of the GTT (Fig. 2B).
The observed glucose intolerance may be attributed to
either decreased peripheral insulin sensitivity or impaired
glucose-stimulated insulin secretion (GSIS). To determine
whether the observed glucose tolerance was the result of
impaired insulin sensitivity, insulin tolerance tests and
hyperinsulinemic-euglycemic clamps were performed.
Both evaluations demonstrated similar insulin sensitivity
for both the PANDER
/ and wild-type mice (Figs. 2C and
D). Evaluation of GSIS was performed by measuring
plasma insulin levels at various time points after glucose
injection. Surprisingly, plasma insulin levels were signiﬁ-
cantly higher in PANDER
/ mice at the 30, 60, and 120
min time points (Fig. 2E). The lack of concordance be-
tween the observed result of glucose intolerance and
higher insulin levels warranted further investigation. To
further measure the in vivo insulin response of PAN-
DER
/ murine islets, we performed administration of the
nonglucose secretagog arginine. The acute insulin re-
sponse (1–5 min after arginine injection) was signiﬁcantly
inhibited in the PANDER
/ mice (Fig. 2F). Overall, these
ﬁndings indicate that PANDER serves a potential role in
the maintenance of postprandial glucose homeostasis.
Decreased hepatic glucose production during hyper-
insulinemic-euglycemic clamp in PANDER
/ mice.
During the hyperinsulinemic-euglycemic clamp, hepatic
glucose production (HGP) was evaluated (Fig. 3A). Basal
HGP was similar between PANDER
/ and wild-type mice
(72.6 
 7.0 vs. 71.1 
 7.5 mg/kg/min, respectively; P  NS).
However, HGP in PANDER
/ mice was signiﬁcantly
lower than in wild-type mice during clamp conditions
(18.6 
 2.1 vs. 29.3 
 4.2 mg/kg/min, respectively; P 
0.05). Percentage of HGP suppression during the clamp
was concordantly higher in PANDER
/ mice but nar-
rowly missed statistical signiﬁcance (73.4 
 3.0 vs. 53.3 

8.9%, respectively; P  0.05) (Fig. 3B).
Loss of PANDER does not impact islet architecture
or gene expression. Because neither insulin sensitivity
nor HGP appeared to be the cause of the observed glucose
intolerance, we next examined if the absence of PANDER
in the pancreatic -cell resulted in altered islet architec-
ture or gene expression. Therefore, immunoﬂuorescence
was performed using antibodies recognizing the pancre-
atic hormones of glucagon and insulin to label the major
islet cells of - and -cells, respectively (Fig. 4A). Both
wild-type and PANDER
/ mice contained both pancre-
atic islet cell types, with insulin-positive -cells localized
to the core of the islet and the smaller glucagon-positive
-cell population localized to the mantle of the islet.
Overall, immunoﬂuorescent evaluation indicated no dis-
cernable difference in islet architecture. To evaluate any
potential differences in mRNA expression for genes in-
volved in GSIS, quantitative RT-PCR was performed on
isolated pancreatic islet RNA (Fig. 4B). The measured islet
genes are involved in multiple steps of GSIS and included
glucose sensing and transport (GLUT2), glycolysis (glu-
cokinase), K
 channel (Kir6.2/Sur1), Ca
2 pumps (sarco-
endoplasmic reticulum Ca
2 ATPase [SERCA]-2/3), and
exocytosis (VAMP2, Rab3a, and Munc18c).
All of the genes were expressed at similar levels for
wild-type and PANDER
/ islet RNA. Western blot analy-
sis of isolated islets from PANDER knockout and wild-
type mice revealed similar expression levels of GK and
Kir6.2, despite the appearance of increased expression via
RT-PCR (data not shown). Overall, intact islet architecture
with similar islet gene expression in the absence of
PANDER demonstrates that the observed glucose intoler-
ance is unlikely to be attributable to impaired islet devel-
opment and rather suggests the potential loss of -cell
function.
Inhibited GSIS from isolated islets of PANDER
/
mice. To further characterize islet function in isolation
and separate from systemic effects, we performed insulin
secretion studies on perifused islets isolated from both
PANDER
/ and wild-type mice (Fig. 5A). Isolated islets
were treated with increasing glucose concentrations rang-
ing from 0–30 mmol/l glucose followed by depolarization
with KCl stimulation. Wild-type islets produced a robust
insulin secretory response to glucose. However, PANDER
/
islets displayed a signiﬁcantly decreased insulin response
to increasing concentrations of glucose compared with
wild-type islets (1.0 
 0.1 vs. 5.3 
 1.7 AUC, respectively;
P  0.05) (Fig. 5B). Both wild-type and PANDER
/ islets
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FIG. 3. HGP during hyperinsulinemic-euglycemic clamp is impaired in
PANDER
/ mice. HPG during the hyperinsulinemic-euglycemic clamps
was determined by subtracting the glucose infusion rate from the
whole-body glucose appearance. Male mice 5–7 months old were
evaluated (n  8). A: Basal HGP and production at the end of the
hyperinsulinemic-euglycemic clamps. B: HGP suppression. Values are
means  SE. *P < 0.05 by Student t test. KO, knockout; WT, wild-type.
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clusion of the experiment (1.7 
 0.2 vs. 3.4 
 1.1 AUC,
respectively; P  NS) (Fig. 5C). To further characterize if
the insulin secretory defect is attributed to decreased
insulin production, insulin content was also measured
from isolated islets (Fig. 5D). Insulin levels were equiva-
lent in both wild-type and PANDER
/ islets (5,272 

1,311 vs. 7,565 
 1,049 ng/ml/50 islets, respectively; P 
NS). Together, these results suggest that PANDER impacts
pancreatic -cell function with a potential role in mediat-
ing GSIS.
PANDER-deﬁcient islets display normal glucose
metabolism with altered Ca
2 response to both
glucose and KCl. The inhibited insulin secretion found
in PANDER
/ islets did not appear to be based at the
level of islet architecture, metabolic gene expression, or
insulin content, and therefore suggested a potential dis-
ruption of glucose metabolism or generation of secondary
signals required for initiating insulin exocytosis. To eval-
uate both glucose metabolism and generation of second-
ary signals, we measured the ATP-to-ADP ratio and
intracellular Ca
2, respectively, from both PANDER
/
and wild-type isolated islets. At physiological glucose
concentrations (2, 5, and 10 mmol/l), the ATP-to-ADP ratio
in PANDER
/ islets was indistinguishable from that of
wild-type islets (data not shown). These results suggest
that glucose metabolism is maintained in PANDER
/
islets, and this was consistent with the maintenance of
normal gene expression of the various metabolic genes of
GLUT2 and glucokinase. For evaluation of secondary
signals, changes in cytosolic Ca
2 during glucose and
KCl stimulation were monitored by fura-2 ﬂuorescence
imaging (Fig. 6). The intracellular Ca
2 response in
PANDER
/ islets differed from that in wild-type islets in
the following ways: hyperresponse of calcium at the
3-mmol/l condition; lack of calcium dip attributed to
SERCA (15,16) immediately preceeding the rapid rise in
intracellular calcium at 16 mmol/l glucose that was ob-
served in wild-type islets; modest descrease in overall
amplitude following 16 mmol/l glucose; and decreased KCl
response. However, both PANDER
/ and wild-type islets
promptly returned to baseline after reaching the 0-mmol/l
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FIG. 4. Normal islet architecture and gene expression in PANDER
/ mice. Pancreatic sections from 4- to 6-month-old male mice were evaluated
via immunoﬂuorescence for detection of insulin (green) and glucagon (red). DAPI nuclear staining is shown in blue. A: Representative
micrographs of insulin- and glucagon-labeled pancreatic sections from PANDER WT (left panel) and PANDER
/ mice (right panel), respectively.
B: Gene expression analysis via RT-PCR in isolated islets of PANDER
/ and WT mice. Various genes involved in GSIS were evaluated in 5- to
7-month-old male mice (n  3). Values are means  SE. P  not signiﬁcant for all genes as determined by Student t test. KO, knockout. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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PANDER
/ mouse islets may potentially indicate a mech-
anism for the impaired GSIS observed in vitro and glucose
intolerance with blunted arginine response observed in
vivo.
Decreased insulin clearance in PANDER
/ mice. The
incongruity of the data indicating a defect in GSIS of the
PANDER
/ islets with the otherwise higher levels of
circulating insulin detected during the GTT potentially
indicated altered insulin clearance, especially in the pres-
ence of normal insulin tolerance. C-peptide is cosecreted
with insulin at equimolar amounts but, in contrast to
insulin, passes the liver without considerable extraction
with a half-life 10-fold higher than that of insulin (17,18).
Therefore, many studies have evaluated insulin clearance
based on the changes in C-peptide–to–insulin ratios deter-
mined at single or multiple time points (19,20). We used
this same indirect approach to investigate potential alter-
ations in hepatic insulin clearance (Fig. 7). Insulin and
C-peptide concentrations increased robustly after glucose
administration for both PANDER
/ and wild-type islets
(Figs. 7A and B). However, as observed previously (Fig.
2E), insulin levels were higher in the PANDER
/ than in
the wild-type mice (Fig. 7A). In contrast, C-peptide levels
were initially higher in PANDER
/ mice, but then similar
to wild-type mice after glucose stimulation (Fig. 7B). The
overall C-peptide–to–insulin ratio was reduced signiﬁ-
cantly in PANDER
/ mice indicating a potential impair-
ment in hepatic insulin clearance (Fig. 7C).
DISCUSSION
The biological function of PANDER has remained elusive
since its initial discovery in 2002. Our previous reports and
a publication from another research group suggested a
potential role for PANDER in glucose homeostasis; how-
ever, the lack of a knockout mouse has hindered further
biological evaluation. Our investigation has attempted to
directly address this limitation via creation of a PANDER
/
mouse and to further establish a functional role for PANDER
in the maintenance of glucose homeostasis.
Targeted disruption of PANDER did not result in in-
creased embryonic lethality or gross morphological differ-
ences between PANDER
/,
/, or wild-type mice.
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FIG. 5. Islet perifusions demonstrate impaired insulin secretion in PANDER
/ mice. A: Pancreatic islets were isolated and evaluated from male
mice 5–7 months old. Islets were isolated and incubated with increasing concentrations of glucose of 0 mmol/l (G0), 2 mmol/l (G2), 5 mmol/l
(G5), 10 mmol/l (G10), and 30 mmol/l (G30) with a terminal step of 30 mmol/l KCl (KCl30) at indicated times. Time at which glucose condition
was increased is shown above and noted on the x-axis. Efﬂuent fractions were collected and insulin was measured by radioimmunoassay (n 
6–7). B: AUC calculated for insulin secretion from the G0 to the G30 condition. C: AUC determined for the insulin secretion during the KCl
condition. D: After conclusion of the perifusion experiment, islets were collected and lysed with acid alcohol, and subsequent measurements of
insulin concentrations were taken via radioimmunoassay. Values are means  SE. *P < 0.05 by Student t test.
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/ male mice displayed glucose intol-
erance, whereas littermate and genotype-matched females
were indistinguishable. However, it is not unusual for a
glucose-intolerant phenotype to be more severe in male
versus female mouse models (21–23). Interestingly, our
PANDER transgenic model also displays a male-speciﬁc
phenotype (6). Deletion of PANDER did not appear to
alter fasting levels of various hormones (i.e., insulin,
glucagon, amylin, or leptin), and the metabolic defect
occurred in the PANDER
/ mice during periods of nutri-
ent challenge (i.e., glucose), suggesting that PANDER serves
a putative role in regulating postprandial glucose homeosta-
sis rather than maintaining basal normoglycemia.
PANDER
/ male mice are glucose intolerant. In addi-
tion, isolated islets appear to exhibit an insulin secretory
defect in response to glucose (in vitro) and arginine (in
vivo) and display an abnormal calcium response to both
glucose and KCl. Indeed, it has been proposed that de-
creased GSIS can be attributed to abnormal Ca
2 handling
of pancreatic islets, as has been reported in the islets
obtained from the type 2 diabetic models of the Goto-
Kakizaki and neonatal streptozotocin rats (24,25). An
additional reported defect in Ca
2 handling has been the
absence of the initial sequestration of Ca
2 by -cell
SERCA found in diabetic db/db murine islets (26). The
initial Ca
2 dip after glucose stimulation is dependent on
functional SERCA and appears to serve a critical role in
GSIS. However, mRNA levels of SERCA 2/3 were similar
between PANDER
/ and wild-type mice, but activity has
yet to be evaluated. Overall, the defective Ca
2 handling
observed in the PANDER
/ islets may provide a caus-
ative mechanism for the impaired GSIS.
A peculiar caveat to our results was discordance between
the higher insulin levels found in vivo during the GTT and
impaired insulin secretion in vitro in the PANDER
/ mice.
Protective and compensatory mechanisms may exist in
vivo that preserve and maintain -cell function, whereas
these defects are substantially exaggerated and identiﬁed
in isolated islets. Also, circulating insulin levels not only
reﬂect secretion but also clearance, and therefore suggest
PANDER
/ mice may also have altered hepatic insulin
clearance. Indeed, our model displayed decreased insulin
clearance, which suggests that PANDER may have a role
in impacting liver function. Alternatively, the decreased
clearance may serve as a compensatory mechanism to
counteract impaired insulin secretion. Interestingly, other
knockout models have also demonstrated a similar phe-
notype of impaired -cell function with in vivo hyperinsu-
linemia. The deletion of hepatocyte nuclear factor-4
(HNF-4) in pancreatic -cells resulted in hyperinsulin-
emia in fasted and fed mice but also demonstrated im-
paired glucose tolerance and abnormal responses of the
isolated HNF-4
/ islets by both islet perifusion and
calcium imaging (27). In addition, the glucagon receptor
knockout (Gcgr
/) mouse demonstrated higher insulin
levels after a tail vein-injected glucose challenge, yet
revealed a blunted glucose-stimulated insulin response in
isolated islets at high glucose concentrations (28). In
Gcgr
/ mice, the impaired GSIS was restored and en-
hanced due to increased levels of biologically active
GLP-1. However, PANDER
/ did not demonstrate in-
creased postprandial serum GLP-1 levels compared with
wild-type mice (data not shown), which suggests that the
incongruity of the observed defect in GSIS with the
otherwise higher levels of circulating insulin detected
during GTT may be the result of altered hepatic function.
Although PANDER
/ mice display impaired GSIS, addi-
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FIG. 6. Abnormal calcium response to glucose stimulation in
PANDER
/ islets. Intracellular calcium concentration was deter-
mined via fura-2 ﬂuorescence imaging during a glucose perifusion on
isolated PANDER
/ and WT islets with stimulation from a glucose
ramp and KCl (n  3). Time of glucose increase is shown above and
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FIG. 7. Decreased insulin clearance in PANDER
/ mice. Intraperitoneal GTT performed by injecting mice with glucose at 2 g/kg and measuring
serum insulin and C-peptide concentrations at the indicated time points. Male mice 5–7 months old were evaluated (n  3–6). Insulin (A) and
C-peptide (B) serum concentrations were determined with commercially available ELISA (ALPCO). C: C-peptide–to–insulin ratio based on AUC
calculated from glycemic levels of insulin and C-peptide measured during the course of the GTT. Values are means  SE. *P < 0.05 by Student
t test.
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in Ca
2 regulation of the pancreatic -cell is causative of
the insulin secretory defect, which is beyond the scope of
this investigation. Further studies are needed to fully
establish the role of PANDER in GSIS and the molecular
mechanism responsible for impaired insulin secretion. The
lack of our PANDER
/ model to develop overt diabetes
or chronic hyperglycemia may be potentially attributed to
PANDER serving multiple functions. The hyperinsuline-
mic-euglycemic clamp studies showed signiﬁcantly de-
creased HGP and a strong trend in increased HGP
suppression compared with wild-type mice. This result
would directly oppose the glucose intolerance observed
during the GTT and could be limiting the higher glycemic
values observed during this assay. Previous literature
showing that PANDER binds to liver membranes and
putatively suppresses insulin action in conjunction
with the PANDER transgenic model demonstrating in-
creased HGP is very consistent with our ﬁndings in the
PANDER
/. Our surprising result in the PANDER
/
mouse certainly suggests that PANDER may be serving
multiple roles in regulating glucose levels via not only the
liver but also through a direct involvement within the
pancreatic islet in either regulation or facilitation of insu-
lin secretion.
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